033270.KS
Korea United Pharm Inc
Price:  
19,000 
KRW
Volume:  
37,759
Korea, Republic of | Pharmaceuticals

033270.KS WACC - Weighted Average Cost of Capital

The WACC of Korea United Pharm Inc (033270.KS) is 8.0%.

The Cost of Equity of Korea United Pharm Inc (033270.KS) is 8.2%.
The Cost of Debt of Korea United Pharm Inc (033270.KS) is 4.25%.

RangeSelected
Cost of equity7.2% - 9.2%8.2%
Tax rate23.1% - 26.2%24.65%
Cost of debt4.0% - 4.5%4.25%
WACC7.0% - 8.9%8.0%
WACC

033270.KS WACC calculation

CategoryLowHigh
Long-term bond rate3.1%3.6%
Equity market risk premium5.8%6.8%
Adjusted beta0.70.75
Additional risk adjustments0.0%0.5%
Cost of equity7.2%9.2%
Tax rate23.1%26.2%
Debt/Equity ratio
0.050.05
Cost of debt4.0%4.5%
After-tax WACC7.0%8.9%
Selected WACC8.0%

033270.KS's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for 033270.KS:

cost_of_equity (8.20%) = risk_free_rate (3.35%) + equity_risk_premium (6.30%) * adjusted_beta (0.7) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.